Objective: To assess the diagnostic delay (DD) and physician-related DD (pDD) in patients with axial spondyloarthritis (SpA) and the potential benefits of a multidisciplinary clinic (MDC) approach. Methods: A retrospective study was undertaken among patients with axial SpA, which aimed to analyse DD, pDD and their risk factors. The influence of pDD on disease outcomes was examined. The pDDs among consecutive SpA patients in an MDC cohort were compared with propensity score matched historical controls (1:1). Results: A total of 208 patients with axial SpA formed the historical control group and 49 patients with axial SpA formed the MDC cohort after introduction of the MDC. The median DD and pDD in the historical controls were 25.5 and 10.0 months, respectively. A cut-off of pDD > 4 months was associated with more active disease and functional impairment. An initial visit to a non-rheumatologist was the most significant risk factor for pDD. Following MDC introduction, the median pDD decreased from 13 months to 1 month after adjustments were made for confounders such as sex, education level, history of smoking, human leukocyte antigen-B27 status and SpA/ankylosing spondylitis classification criteria.
Introduction
Ankylosing spondylitis (AS) is a chronic disabling inflammatory disorder primarily affecting enthesis and axial skeleton joints. [1] [2] [3] Due to the insidious onset of the symptoms such as low back pain, along with the slow radiographic progression of the disease (according to the modified New York criteria 4 ), prolonged diagnostic delay (DD) is a well-recognized feature of AS management. [5] [6] [7] [8] [9] The DDs in AS, or the time interval between the onset of the symptoms and the correct diagnosis being made, were reported to range from 5 to 10 years. 1, 3, 5 To identify the disease at an early stage, the Assessment of Spondyloarthritis International Society (ASAS) proposed new criteria for axial spondyloarthritis (SpA). 10 Axial SpA includes not only classic AS, but also nonradiographic disease, for which sensitive imaging such as magnetic resonance imaging has improved the ability to achieve an early diagnosis. 5, 7 However, DD still remains an issue in axial SpA, with a reported time gap of 2-8 years.
11 -13 It has been proposed that early diagnosis is probably related to better outcomes for axial SpA. 6, 14 Patients with late diagnosis (> 5 years) have significantly higher structural damage and more severely limited spinal mobility. 6 In addition, early diagnosis is crucial in order to increase the chance of achieving treatment targets. 14 Physicians play an important role in the early identification of disease, but in clinical practice in mainland China, due to a lack of a fully developed screening and triage system for rheumatic diseases by general practitioners, patients 'randomly' choose different medical specialists without professional guidance. Thus, physician-related DD (pDD), which is defined as the time interval between the initial visit to a physician and the time of axial SpA diagnosis, may contribute significantly to the overall DD. In this regard, the present study aimed to assess the DD and pDD of patients with axial SpA in a clinic in Shanghai, China. The risk factors and potential solutions to reduce DD or pDD were explored.
Patients and methods

Study design and patients
This retrospective study enrolled patients with axial SpA who visited the Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China between April 2014 and February 2016. The primary aim of the study was to investigate the DD and pDD of patients with axial SpA in this clinic. All patients fulfilled the axial SpA classification criteria of the ASAS, 10 and/or the modified New York criteria for AS. 4 Peripheral SpA and patients with psoriasis or inflammatory bowel disease were excluded. The DD and pDD in all axial SpA/AS patients were analysed and the relevant risk factors were identified. These patients were considered the historical controls.
The secondary aim of the study was to evaluate whether a multidisciplinary clinic (MDC) could shorten the pDD. An MDC was created in March 2016 in Renji Hospital, School of Medicine, Shanghai Jiaotong University, which composed of a rheumatologist (T.L.) and an orthopaedic surgeon (W.X.), who were responsible for the final diagnostic decision-making. In addition, a nurse specialist (C.Y.) and a medical assistant (J.H.), both of whom had received an arthritis nurse-training programme from the Prince Wales Hospital (Hong Kong), also played essential roles in the MDC. For this part of the study, consecutive newly diagnosed patients with axial SpA were enrolled between March 2016 and February 2017 by the MDC clinic using the same inclusion/exclusion criteria as described above. The pDDs and DDs in the MDC cohort were compared with the propensity score matched historical controls (1:1).
The study protocol was approved by the Institutional Review Board of Renji Hospital (no. 2013084k). The written informed consent was acquired from each patient and patient anonymity was ensured. Mann-Whitney U-test. Analysis of covariance (ANCOVA) was used to illustrate the influence of pDD on disease activity, physical function and axial flexibility. Two-sided P-values < 0.05 were considered statistically significant.
Data collection
Results
The first part of this retrospective study enrolled 208 patients with axial SpA to provide historical control data regarding DD and pDD. Their demographic and clinical characteristics are summarized in Table 1 . The mean AE SD age of this patient group was 35.5 AE 12.8 years and 149 (71.6%) were male. According to the available radiographic data at the time of diagnosis, 128 of 179 (71.5%) fulfilled the AS criteria. HLA-B27 positivity was demonstrated in 158 of 185 (85.4%) patients. The overall median (IQR) DD was 25.5 (4.0, 74.8) months and the overall mean AE SD DD was 57.9 AE 81.0 months. The median (IQR) pDD was 10.0 (0.5, 59.3) months. The median (IQR) disease duration after diagnosis to the time of retrospective chart review was 9.5 (0.0, 51.8) and the mean AE SD was 40.8 AE 65.1 months. Of note, during this period, 108 of 208 (51.9%) patients had prior exposure to at least one TNFi treatment.
Patients with a cut-off of pDD > 4 months showed significantly higher BASDAI and BASMI scores than those with pDD 4 months (P ¼ 0.025 and P ¼ 0.004, respectively; Table 2 ). These differences of BASDAI and BASMI scores between the two groups were similar (P ¼ 0.025 and P ¼ 0.003, respectively) after adjustment for the time since diagnosis and exposure to TNFi using ANCOVA.
Male patients and patients with HLA-B27, history of smoking, patients with AS (compared with non-radiographic axial SpA [nr-aSpA]) and those who had an initial visit to a non-rheumatologist had a significantly longer overall DD (Table 3) (P < 0.05 for all comparisons). Moreover, pDD was significantly longer in patients who initially visited to a nonrheumatologist and in patients with a lower education level (<9 years). With regard to physician speciality, 125 of 208 (60.1%) patients had their first consultation with an orthopaedist, but only 42 of 208 (20.2%) patients received their diagnosis The difference of pDD was compared between the MDC cohort (n ¼ 49) and the historical controls. Propensity scores (1:1) were used to match all the relevant confounders, e.g. sex, history of smoking, HLA-B27, AS or nr-aSpA diagnosis and education level ( Table 4 ). The median pDD was significantly shorter in the MDC cohort compared with the historical controls (1.0 versus 13.0 months, respectively; P ¼ 0.026). The median overall DD was also significantly shorter in the MDC cohort compared with the historical controls (12.0 versus 46.0 months, respectively; P ¼ 0.049) ( Table 5 ).
Discussion
The issue of DD in axial SpA/AS, and pDD in particular, to some extent reflect the efficiency of the health system dealing with this disease. According to this current retrospective study, the median (IQR) overall DD was 25.5 (4.0-74.8) months and the median (IQR) pDD was 10.0 (0.5-59.3) months in the historical controls. These current findings were comparable with a recent cross-sectional study undertaken in France, which reported a median DD of 2.0 years; 13 but significantly longer than another study from Spain, which reported a median DD of 4.2 months. 18 The direct comparison of DDs among studies is difficult not only because of the disparities in the models of health care delivery, but also because of the subjective nature of the patients' reporting of their symptom onset. The estimates of overall DD are likely to be less reliable than the measurement of pDD, which relies on documented dates in the patient's medical records. Furthermore, these current data demonstrated that a pDD with a cutoff > 4 months was associated with more active disease and more functional impairment, even after adjusting for treatment exposure to TNFi biological agents. This underscores the significance of prolonged pDD in terms of its impact on disease outcome.
To further investigate the possible factors that contribute to pDD, the current study observed that an initial visit to a non-rheumatologist was the most significant risk factor. Only 21 of 208 (10.1%) patients had their first consultation with a rheumatologist and 125 of 208 (60.1%) patients initially saw an orthopaedist. In contrast, 143 of 208 (68.8%) patients received their diagnosis of axial SpA from a rheumatologist and only 42 of 208 Non-parametric Mann-Whitney U-test; b Adjusted for the time since diagnosis and exposure to tumour necrosis factor inhibitor using analysis of covariance; NS, not statistically significant (P ! 0.05).
(20.2%) patients received their diagnosis of axial SpA from an orthopaedist. These findings appear to be unique to our clinical centre and should only be cautiously extrapolated to a wider region. For example, in a study of 102 patients with axial SpA in Korea, the specialities of the physicians who were involved before the Data presented as median (interquartile range). *P < 0.05; **P < 0.01; non-parametric Mann-Whitney U-test. HLA, human leukocyte antigen; AS, ankylosing spondylitis; nr-aSpA, non-radiographic axial SpA; NS, not statistically significant (P ! 0.05).
diagnosis of SpA being made by a rheumatologist included orthopaedists (86%), neurosurgeons (28%), general physicians (5%), physiatrists (5%) and others (22%).
11
A study in Japan showed that 69% of the patients with AS visited two or more doctors prior to AS diagnosis and orthopaedic surgeons were the most commonly visited (62%). 19 In Indian patients with AS, most incorrect initial diagnoses were made by orthopaedists (75.9%), followed by general physicians (50%) and rheumatologists (12%). 20 Thus, setting up an MDC combining a rheumatologist and an orthopaedist working together would appear to be a reasonable way to reduce the pDD in axial SpA.
The MDC is a well-recognized working model designed to deliver patient-centred care by centralizing relevant practitioners at a single physical site. Evidence has Figure 1 . The physician's speciality at the first consultation compared with the speciality of the physician who made the diagnosis of axial spondyloarthritis (SpA) in patients (n ¼ 208) who participated in a study of the risk factors associated with diagnostic delay. shown that the MDC model is associated with improved efficiency and completeness of care for many chronic diseases. [21] [22] [23] Indeed, the current data demonstrated that the pDD was significantly shorter in patients with axial SpA who were managed by the MDC compared with the propensity score matched historical controls (1 versus 13 months, P ¼ 0.026), after adjustments for possible confounders such as sex, education level, history of smoking, HLA-B27 status and SpA/AS criteria.
In conclusion, the formation of an MDC appears to be a promising approach to partially solving the problem of pDD in patients with axial SpA, although followup studies to see whether patients managed by the MDC ultimately have a better longterm outcome will be crucial to further validate this approach.
